SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhood is trending as users report widespread platform outages, potentially linked to Amazon Web Services, sparking frustration and concerns about accessibility during trading. The community is debating the cause of the issues, with some questioning the reliability of the platform and others attributing it to broader internet service disruptions. Despite the technical difficulties, the stock price has shown surprising resilience, leading to discussions about market dynamics and potential manipulation.

GSI Technology, Inc. engages in the design, development and marketing of memory products primarily for the networking, and telecommunications markets. Its product includes Static Random Access Memory, or SRAM, which incorporated in networking and telecommunications equipment, such as routers, switches, wide area network infrastructure equipment, wireless base stations and network access equipment. It also offers services to the ongoing needs of the military, industrial, test and measurement equipment, automotive and medical markets for SRAMs .The company was founded by Lee-Lean Shu and Robert Yau in March 1995 and is headquartered in Sunnyvale, CA.

GSI Technology Inc

GSIT is trending due to positive news regarding its APU CIM architecture achieving GPU-class AI performance with significantly lower energy consumption, sparking community discussion about potential buyouts and comparisons to other AI and chip companies like NVDA. The community is actively debating whether the stock is primed for a short squeeze and discussing strategies to capture further upside. Some traders express concerns about potential dilution and the company's history, while others focus on the potential for long-term growth in the AI and edge computing sectors.

Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip Astley-Sparke, Colin A. Love, and Robert Coffin in March 2015 and is headquartered in Woburn, MA.

Replimune Group Inc

Replimune ($REPL) is trending due to news of the FDA accepting the resubmission of its Biologics License Application for RP1, a melanoma treatment, leading to significant price movement and trading volume. Community discussions revolve around updated price targets, the potential for a short squeeze, and collaborations with major pharmaceutical companies. However, some traders express caution, citing the long PDUFA timeline and potential for a pump and dump.

Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA.

Verastem Inc

Verastem ($VSTM) is trending as investors discuss the implications of new data, with some citing a strong response rate in lung cancer patients from a GenFleet study. While some view the sell-off as an overreaction or manipulation, others question the long-term impact and management's spending. The community is actively debating the data's significance and comparing it to competitors in the KRAS G12D space.

Cleveland-Cliffs, Inc. is a flat-rolled steel company, which engages in provision of iron ore pellets to the North American steel industry. It focuses on the production of metallic and coke, iron making, steelmaking, rolling and finishing, and downstream tubular components, stamping, and tooling. The company was founded in 1847 and is headquartered in Cleveland, OH.

Cleveland-Cliffs Inc

Cleveland-Cliffs is trending as the company explores rare earth production at its U.S. mining sites, potentially pivoting from steel to strategic minerals. Community members are weighing in on the CEO's vision, buyout possibilities, and the potential impact of this move on debt reduction and shareholder value. Some traders express concerns about the CEO's past performance and the sustainability of the recent surge.

FLOKI is the utility token of the Floki Ecosystem. The Floki Ecosystem is a community-powered ecosystem that aims to give people control of their finances through four key utility offerings:  - The Valhalla NFT Metaverse Game. - The Floki University Crypto Education platform. - DeFi. - The FlokiPlaces NFT & Merchandise Marketplace.

Floki Token

Floki is trending as the community anticipates potential benefits from its recent listing on Robinhood. Discussions revolve around whether this listing will act as a catalyst for price appreciation, with some drawing comparisons to Dogecoin's earlier success, while others point to Floki's unique utility and deflationary mechanisms.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including from sellers, advertising, and subscription services through internationally-focused online stores. The AWS segment is composed of global sales of compute, storage, database, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazon's stock is trending due to a significant AWS outage impacting numerous websites and services, sparking concerns about the company's reliability and the internet's dependency on its cloud infrastructure. While some traders anticipate a dip due to potential customer refunds and reputational damage, others see the event as a reminder of AWS's central role in the digital economy, viewing it as a buying opportunity. Community discussions revolve around the outage's impact on various sectors and whether it will affect Amazon's upcoming earnings.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apple is trending as the stock flirts with all-time highs, driven by positive sentiment around iPhone 17 sales and potential AI integration. Community discussions revolve around analyst upgrades, revenue projections, and the ongoing battle for AI talent with companies like Meta. Some investors express concerns about valuation and potential market corrections, while others remain bullish, anticipating a continued rally.

Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. The firm's proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.

Celcuity Inc

CELC is trending after Phase 3 trial results showed significant improvement in survival rates for HR+/HER2- breast cancer patients, leading to analyst upgrades and community excitement. Some traders are discussing potential buyout scenarios and the possibility of this therapy becoming the new standard of care. However, caution is also present as some community members point to potential dilution and the need for further catalysts.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

Recent news regarding the company's CEO taking a board seat at TLPH is sparking community interest, especially given CRMD's strategic investment in TLPH. Some investors speculate about a potential acquisition, while others are focused on upcoming clinical data for TLPH's Niyad and its potential impact on CRMD's growth. Bullish sentiment seems to be driven by institutional buying and anticipation of upcoming earnings and guidance.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Celcuity Inc. (CELC) stock surged about 221% on Monday morning after the company announced that its experimental combination treatment demonstrated a reduction in the risk of disease progression or death in patients with a type of advanced breast cancer in a late-stage study.The firm <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.celcuity.com/press-releases/">said</a> that the combination of Gedatolisib, Fulvestrant, and Palbociclib reduced the risk of disease progression or death by 76% compared to Fulvestrant alone in patients with previously treated HR+/HER2- advanced breast cancer.Median progression-free survival was 9.3 months with the Gedatolisib triplet compared to two months with Fulvestrant alone, meaning patients lived an average of 9.3 months without progression of disease with the treatment.A combination of Gedatolisib plus Fulvestrant reduced the risk of disease progression or death by 67% compared to Fulvestrant, with a median progression-free survival of 7.4 months.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/CELC">Celcuity</a> trended in the ‘extremely bullish’ territory over the past 24 hours, while message volume remained at ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:625/61;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_28_at_9_01_25_AM_png_aec1ab2846.webp" alt="CELC's Sentiment Meter and Message Volume as of 9 a.m. ET on July 28, 2025 | Source: Stocktwits" width="625" height="61"><figcaption>CELC's Sentiment Meter and Message Volume as of 9 a.m. ET on July 28, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user opined that they expect a peak market valuation of three to five billion dollars for the company.<stembedurl>https://stocktwits.com/BIOTECH_GURU/message/622681433</stembedurl>Another said that the news is worth at least a 500% rally.<stembedurl>https://stocktwits.com/madape/message/622680399</stembedurl> Breast cancer is the second most common cancer and one of the leading causes of cancer-related deaths worldwide. According to Celcuity, HR+/HER2- breast cancer is the most common subtype of breast cancer, accounting for approximately 70% of all breast cancers.The improvements in progression-free survival observed in the study with the combinations were statistically significant and clinically meaningful, the company said.Both the combinations were better tolerated than observed in an early-stage trial in patients with advanced breast cancer, it added.Sara Hurvitz, co-principal investigator for the trial, said that the data for both combination treatments in the trials are “potentially practice-changing.”“The efficacy improvement relative to the control that each of the gedatolisib regimens demonstrated was historic for this patient population,” CEO Brian Sullivan added.Celcuity expects to submit a new drug application for Gedatolisib to the U.S. Food and Drug Administration in the fourth quarter of 2025.CELC stock is up by about 238% this year and by 147% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/weride-receives-autnomous-driving-permit-in-saudi-arabia/choeFojR5Dy">WeRide Receives Autonomous Driving Permit in Saudi Arabia: Retail Sees Stock Hitting $20</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

This Pharma Stock Rose 200% On Monday Morning And Retail Says Valuation Could Rise To $5B: Here’s Why

Sara Hurvitz, co-principal investigator for the trial, said that the data for both combination treatments in the trials are “potentially practice-changing.”

Equity

Sara Hurvitz, co-principal investigator for the trial, said that the data for both combination treatments in the trials are “potentially practice-changing.”


Top Five Cancer Types Dominate New US Cases as Biotech Sector Eyes $314B Market by 2032

Top Five Cancer Types Dominate New US Cases as Biotech Sector Eyes $314B Market by 2032 Top Five Cancer Types Dominate New US Cases as Biotech Sector Eyes $314B Market by 2032 PR Newswire VANCOUVER...

Celcuity To Present at Upcoming Needham and Stifel Investor Conferences

MINNEAPOLIS, April 04, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that...

Celcuity Inc.'s (NASDAQ:CELC) large institutional owners must be happy as stock continues to impress, up 12% over the past week

Key Insights Institutions' substantial holdings in Celcuity implies that they have significant influence over the...

Celcuity (NASDAQ:CELC) Price Target Increased to $24.00 by Analysts at Needham & Company LLC

Celcuity (NASDAQ:CELC - Free Report) had its price target hoisted by Needham  Company LLC from $23.00 to $24.00 in a research report released on Thursday, Benzinga reports. Needham  Company...

Celcuity (NASDAQ:CELC - Get Free Report) had its price objective increased by equities researchers at Needham & Company LLC from $23.00 to $24.00 in a research report issued to clients and investors...

Celcuity (NASDAQ:CELC) Given New $25.00 Price Target at Craig Hallum

Celcuity (NASDAQ:CELC  Free Report) had its target price lifted by Craig Hallum from $20.00 to $25.00 in a report issued on Thursday morning, Benzinga reports. The firm currently has a buy...

Celcuity Inc.'s Balancing Act: Navigating Financial Risks in Capital Raising Endeavors

Celcuity Inc. (CELC) has disclosed a new risk, in the Share Price & Shareholder Rights category. Celcuity Inc. faces significant financial risks as...

Celcuity (CELC, $21.58) RSI Indicator left the overbought zone on March 28, 2024

This is a signal that CELC's price could be shifting from an uptrend to a downtrend. Traders may consider selling the stock or exploring put options...

Celcuity (CELC, $21.58) Moving Average Convergence Divergence (MACD) Histogram turned positive on March 28, 2024

This is a Bullish indicator signaling CELC's price could rise from here. Traders may explore going long the stock or buying call options...

Will Netflix ($NFLX) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Netflix Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

Current Price	$72.18
Prev Close	$51.96
Open	$79.37
Dividend Yield	0.00%
50-Day Moving Average	$51.66
Beta	0.87
Avg. Volume	841,271.52
PE Ratio	-15.07

52-Week High	$63.06
52-Week Low	$7.58
Market Capitalization	$2.2B
EPS (Annual)	-$2.83
Price to Book	45.57
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

CELC
Celcuity Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest CELC News

CELCCelcuity Inc